Screener
ARS Pharmaceuticals, Inc. SPRY Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026. Open the filing →
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
FAQ
- What is ARS Pharmaceuticals, Inc.'s invested capital?
- ARS Pharmaceuticals, Inc. (SPRY) reported invested capital of $133.51M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s invested capital changed year-over-year?
- ARS Pharmaceuticals, Inc.'s invested capital decreased by 29.4% year-over-year, from $189.18M to $133.51M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s invested capital?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s invested capital has grown at a -15.7% compound annual growth rate (CAGR), from -$397.75M to $169.32M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about ARS Pharmaceuticals, Inc.'s invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude